Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non‐metastatic breast cancer

AIMS: Trastuzumab, an antibody binding to epidermal growth factor receptor‐2 (HER2), has been approved to treat HER2‐positive breast cancer in different settings. This study aimed at evaluating the influence of tumour size on trastuzumab pharmacokinetics (PK) in non‐metastatic breast cancer patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Clin Pharmacol
Main Authors: Bernadou, Guillemette, Campone, Mario, Merlin, Jean‐Louis, Gouilleux‐Gruart, Valérie, Bachelot, Thomas, Lokiec, François, Rezai, Keyvan, Arnedos, Monica, Diéras, Véronique, Jimenez, Marta, Paintaud, Gilles, Ternant, David
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2016
Teme:
Pharmacokinetics
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4834606/
https://ncbi.nlm.nih.gov/pubmed/26714164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12875
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki